Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Cipla Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (476)
Cancellation by sponsor (195)
Cancellation or suspension (77)
Prescription medicine registration (37)
Cancellation for failure to pay annual charge (17)
Australian Public Assessment Report (AusPAR) (4)
Prescription medicine decision summary (4)
Prescription medicine evaluation (1)

Date

2024 (73)
2023 (102)
2022 (74)
2021 (76)
2020 (120)
2019 (22)
2018 (69)
2017 (106)
2016 (31)
2015 (36)
2014 (21)
2013 (9)
2012 (5)
2011 (6)
2010 (20)
2009 (5)
2008 (3)
2007 (6)
2006 (7)
2005 (2)
2004 (2)
2003 (4)
2002 (3)
2001 (4)
2000 (1)
1999 (2)
1998 (1)
1996 (1)

Results for "[search-keyword]"

Search

Sponsor content

811 result(s) found, displaying 221 to 230

Trastucip and Tuzucip

29 July 2022

Prescription medicine decision summary

TGA decision: Trastucip and Tuzucip (trastuzumab) are approved to treat breast cancer.
TRASTUCIP, TUZUCIP (Cipla Australia Pty Ltd)

7 July 2022

Prescription medicine registration

Active ingredients: Trastuzumab.
LACORESS lacosamide 100 mg film-coated tablet blister pack (337933)

11 May 2021

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LACORESS lacosamide 100 mg film-coated tablet blister pack.
LACORESS lacosamide 150 mg film-coated tablet blister pack (337903)

11 May 2021

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LACORESS lacosamide 150 mg film-coated tablet blister pack.
LACORESS lacosamide 200 mg film-coated tablet blister pack (337917)

11 May 2021

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LACORESS lacosamide 200 mg film-coated tablet blister pack.
LACORESS lacosamide 50 mg film-coated tablet blister pack (337894)

11 May 2021

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LACORESS lacosamide 50 mg film-coated tablet blister pack.
TRUST FEMZOLE DUO clotrimazole 10mg/g cream tube and fluconazole 150mg capsule Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
Suspended from ARTG - PRICELINE REFLUX RELIEF EXTRA STRENGTH ranitidine 300mg (as hydrochloride) capsule-shaped tablet blister strip pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
Suspended from ARTG - CIPLA RANITIDINE 300 ranitidine (as hydrochloride) 300 mg tablet strip pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
Suspended from ARTG - RANCIP 300 ranitidine (as hydrochloride) 300 mg tablet strip pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd

Pages

First page
Previous page
…
Page 19
Page 20
Page 21
Page 22
Current page 23
Page 24
Page 25
Page 26
Page 27
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.